Get the Stockscreener App
11.70
0.34%
-0.04
Olema Pharmaceuticals Inc stock is traded at $11.70, with a volume of 806.73K.
It is down -0.34% in the last 24 hours and up +5.03% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$11.74
Open:
$11.74
24h Volume:
806.73K
Relative Volume:
0.59
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-185.15M
P/E Ratio:
-5.7769
EPS:
-2.0253
Net Cash Flow:
$-148.72M
1W Performance:
+2.01%
1M Performance:
+5.03%
6M Performance:
-53.63%
1Y Performance:
+156.02%
1-Day Range:
$11.54
$11.85
1-Week Range:
$10.71
$11.85
52-Week Range:
$4.47
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
11.70 | 1.02B | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-19-26 | Resumed | Jefferies | Buy |
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Form 144 Olema Pharmaceuticals For: 24 July By Investing.com - Investing.com South Africa
Olema Pharmaceuticals launches recruitment drive for medical science liaison role - Traders Union
OLMA (NASDAQ: OLMA) insider plans Rule 144 sale of 12,500 common shares - Stock Titan
Siren L.L.C. Boosts Stake in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
339,461 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by SEB Asset Management AB - MarketBeat
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Jennison Associates LLC Has $27.17 Million Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9%Here's Why - MarketBeat
Olema Pharmaceuticals appoints Brad Lanoue as vice president of market access - Traders Union
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell" - MarketBeat
Enterprise value to EBIT forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Price to earnings forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Price to earnings forward of Olema Pharmaceuticals, Inc. – BOATS:OLMA - TradingView
Price to book forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Olema Pharmaceuticals (OLMA) Jefferies London Healthcare Conference 2025 Summary - Quartr
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – BOATS:OLMA - TradingView
Enterprise value to revenue forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Price to sales forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Olema Pharmaceuticals (OLMA) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesInvestor Earnings Call - dars.gov.et
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals (OLMA) Q1 2026 Earnings: EPS Beats Estimates Amid Continued R&D ProgressEnergy Earnings Report - DonanımHaber
Olema Pharmaceuticals opens director clinical science role to advance cancer trial programs - Traders Union
Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index InclusionHas The Bull Case Changed? - simplywall.st
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story? - Yahoo Finance
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2500 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2000 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell 3000E Growth Benchmark - marketscreener.com
Olema Pharmaceuticals (OLMA) Holds Steady Near Support Amid Minor DeclineUp Down Volume - dars.gov.et
Olema Pharmaceuticals (OLMA) Holds Steady Near Support After Minor DeclineHidden Order - dars.gov.et
Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA) - TradingView
OLMA Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Australia
Olema (NASDAQ: OLMA) awards director 29,500 stock options - Stock Titan
BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants - Stock Titan
Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51 - Stock Titan
Olema Pharmaceuticals (OLMA) director awarded 29,500 stock options at $9.51 strike price - Stock Titan
Olema (OLMA) director Garland J. Scott awarded 29,500 stock options at $9.51 - Stock Titan
[Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Olema Pharmaceuticals (OLMA) director granted 29,500 stock options at $9.51 strike - Stock Titan
Olema (OLMA) director receives 29,500 options at $9.51 strike price - Stock Titan
Olema (OLMA) director granted 29,500 stock options at $9.51 exercise price - Stock Titan
Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price - Stock Titan
Olema (OLMA) director Graham Walmsley awarded 29,500 stock options at $9.51 - Stock Titan
Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young - Stock Titan
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):